Clinical trial
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate…
NCT00401765 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00401765 |
|---|---|
| Title | A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer |
| Official title | A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Combined With Docetaxel in Subjects With Metastatic Hormone-Refractory Prostate Cancer |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | CNTO 328, Docetaxel |
| Enrollment | 40 |
| Start date | Sep 1, 2005 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Nov 22, 2006 |
| Last update posted | May 26, 2014 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: